149 related articles for article (PubMed ID: 38324106)
1. Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis.
Rubino M; Di Stasio GD; Bodei L; Papi S; Rocca PA; Ferrari ME; Fodor CI; Bagnardi V; Frassoni S; Mei R; Fazio N; Ceci F; Grana CM
Endocrine; 2024 May; 84(2):704-710. PubMed ID: 38324106
[TBL] [Abstract][Full Text] [Related]
2. Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Zandee WT; Feelders RA; Smit Duijzentkunst DA; Hofland J; Metselaar RM; Oldenburg RA; van Linge A; Kam BLR; Teunissen JJM; Korpershoek E; Hendriks JM; Abusaris H; Slagter C; Franssen GJH; Brabander T; De Herder WW
Eur J Endocrinol; 2019 Jul; 181(1):45-53. PubMed ID: 31067510
[TBL] [Abstract][Full Text] [Related]
3. Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas.
Nastos K; Cheung VTF; Toumpanakis C; Navalkissoor S; Quigley AM; Caplin M; Khoo B
J Surg Oncol; 2017 Mar; 115(4):425-434. PubMed ID: 28166370
[TBL] [Abstract][Full Text] [Related]
4.
Parghane RV; Talole S; Basu S
Ann Nucl Med; 2021 Jan; 35(1):92-101. PubMed ID: 33135123
[TBL] [Abstract][Full Text] [Related]
5. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma.
Kong G; Grozinsky-Glasberg S; Hofman MS; Callahan J; Meirovitz A; Maimon O; Pattison DA; Gross DJ; Hicks RJ
J Clin Endocrinol Metab; 2017 Sep; 102(9):3278-3287. PubMed ID: 28605448
[TBL] [Abstract][Full Text] [Related]
7. [
Prado-Wohlwend S; Del Olmo-García MI; Bello-Arques P; Merino-Torres JF
Front Endocrinol (Lausanne); 2022; 13():778322. PubMed ID: 35197929
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of peptide receptor radionuclide therapy in patients with advanced pheochromocytoma and paraganglioma: A single-institution experience and review of the literature.
Tang CYL; Chua WM; Huang HL; Lam WW; Loh LM; Tai D; Ong SYK; Yan SX; Loke KSH; Ng DC; Tham WY
J Neuroendocrinol; 2023 Dec; 35(12):e13349. PubMed ID: 37937484
[TBL] [Abstract][Full Text] [Related]
9. Polish experience in Peptide receptor radionuclide therapy.
Kunikowska J; Królicki L; Sowa-Staszczak A; Hubalewska-Dydejczyk A; Pawlak D; Mikolajczak R; Handkiewicz-Junak D; Szaluś N; Kamiński G; Cwikla J; Jakuciński M; Lukiewicz A; Kowalska A; Gut P
Recent Results Cancer Res; 2013; 194():467-78. PubMed ID: 22918776
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of peptide receptor radionuclide therapy with
Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhang J; Zhu Z; Chen X
Theranostics; 2022; 12(15):6437-6445. PubMed ID: 36185603
[No Abstract] [Full Text] [Related]
12. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma.
Forrer F; Riedweg I; Maecke HR; Mueller-Brand J
Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):334-40. PubMed ID: 18480742
[TBL] [Abstract][Full Text] [Related]
13. Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy.
Gabriel M; Nilica B; Kaiser B; Virgolini IJ
J Nucl Med; 2019 Apr; 60(4):524-529. PubMed ID: 30115690
[TBL] [Abstract][Full Text] [Related]
14. Response to targeted radionuclide therapy with [
Prado-Wohlwend S; Del Olmo-García MI; Bello-Arques P; Merino-Torres JF
Front Endocrinol (Lausanne); 2022; 13():957172. PubMed ID: 36339441
[TBL] [Abstract][Full Text] [Related]
15. Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials.
Severi S; Bongiovanni A; Ferrara M; Nicolini S; Di Mauro F; Sansovini M; Lolli I; Tardelli E; Cittanti C; Di Iorio V; Mezzenga E; Scarpi E; Ibrahim T; Paganelli G; Zovato S
ESMO Open; 2021 Aug; 6(4):100171. PubMed ID: 34139487
[TBL] [Abstract][Full Text] [Related]
16. Salvage peptide receptor radionuclide therapy with [
van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models.
Ullrich M; Richter S; Liers J; Drukewitz S; Friedemann M; Kotzerke J; Ziegler CG; Nölting S; Kopka K; Pietzsch J
Theranostics; 2023; 13(1):278-294. PubMed ID: 36593963
[TBL] [Abstract][Full Text] [Related]
18. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
19. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy.
Seregni E; Maccauro M; Chiesa C; Mariani L; Pascali C; Mazzaferro V; De Braud F; Buzzoni R; Milione M; Lorenzoni A; Bogni A; Coliva A; Lo Vullo S; Bombardieri E
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):223-30. PubMed ID: 24233003
[TBL] [Abstract][Full Text] [Related]
20. High-Specific-Activity-
Jha A; Taïeb D; Carrasquillo JA; Pryma DA; Patel M; Millo C; de Herder WW; Del Rivero J; Crona J; Shulkin BL; Virgolini I; Chen AP; Mittal BR; Basu S; Dillon JS; Hope TA; Mari Aparici C; Iagaru AH; Hicks RJ; Avram AM; Strosberg JR; Civelek AC; Lin FI; Pandit-Taskar N; Pacak K
Clin Cancer Res; 2021 Jun; 27(11):2989-2995. PubMed ID: 33685867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
